Gynecologic Cancer | Norton Healthcare

Indication: Gynecologic Cancer

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without

Sub-indication: Gynecologic Cancer

Drug Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Learn more at ClinicalTrials.gov

Email for more information: GYN-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.